Malaria, Cerebral
Conditions
Keywords
severe malaria, children, adjunctive treatment
Brief summary
The purpose of this study is to assess if adding inhaled Nitric Oxide to other malaria treatments can improve the outcome of cerebral malaria in children aged 2months to 12 years.
Detailed description
Despite very effective antimalarial treatment, there is a residual and unacceptable high mortality rate of malaria, especially amongst young children. Recent progress has been made in understanding the role of Nitric Oxide (NO) in severe malaria, indicating that NO supplementation is likely to have a beneficial action in severe malaria possibly through down-regulation of inflammatory cytokines like TNF. Of the various ways to supplement NO, iNO appears to be the safest since it is very well studied in critically ill patients and does not cause systemic vasodilation. The safety of NO inhalation has been clearly demonstrated through its wide use in the treatment of persistent pulmonary hypertension in neonates and pulmonary hypertension in children and adults. Extensive data on its safety has been collected. This study is a phase 2 clinical trial that aims at demonstrating the efficacy of iNO when added to antimalarial treatment to treat cerebral malaria. This study will also provide a better understanding of the pathophysiological mechanisms involved in severe malaria.
Interventions
DRUGinhaled nitric oxide
Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
DRUGPlacebo
The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Sponsors
Mbarara University of Science and Technology
Massachusetts General Hospital
Harvard Medical School (HMS and HSDM)
Medecins Sans Frontieres, Netherlands
Epicentre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Months to 12 Years
Healthy volunteers
No
Inclusion criteria
* Age between 2 months and 12 years. * With malaria infection confirmed by a malaria antigen test and/or a positive blood smear examination * AND sustained coma: achieving a Blantyre Coma Score less than 3 for 2, or more, hours after ruling out and treating hypoglycemia (blood glucose less than 2.2 mmol/l), ruling out meningitis, and ruling out and treating active clinical seizures.
Exclusion criteria
* Refusal to participate * Other cause of coma (toxic or pre-existing severe neurological disease) * Terminal respiratory failure (due to brainstem coning) * Coagulopathic * Clinically unstable enough to preclude venipuncture and phlebotomy * Severe malnutrition defined by edema or a weight-for-height minus 3 SD; * Evidence of pre-existing brain injury * Advanced AIDS defined by WHO clinical staging 4;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Angiopoietin 1 (Ang-1) | 48 hours | Increase in Ang-1 between inclusion and 48 hours of combined therapy (iNO or placebo plus antimalarial chemotherapy) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| coma score | 48 hours | normalisation of coma score (Blantyre coma scale) |
| retinopathy | every 6 hours | Normalisation of malaria retinopathy measured by indirect fundoscopy |
| tone | 48 hours | Improvement of posture and tone |
| Mortality | 48 hours | Reduction in mortality at 48 hours |
| Vital signs | every 6 hours | Improvement of vital signs: Systolic and diastolic blood pressure, pulse rate, temperature |
| oxygen saturation | every 6 hours | Both Hb Oxygen saturation (SpO2) and total MetHb levels continuously measured by pulse oximetry (Rascal Model 7, Massimo Corp.) |
| Measure of occurrence of neurological sequelae in children | months 1, 3 and 6 | Reduction of incidence of neurological sequelae, including motor dysfunction, behavioral disorders, hearing, speech and sight disorders and seizure disorders. |
Countries
Uganda
Outcome results
None listed